Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

How to Invest in the Growing Autism Care Economy

BY | ETF Database
12:45 pm ET 09/01/26 | 4 VIEWS
  • Related Symbols
  • ASD
The autism care economy is expanding across healthcare, technology, education, and behavioral services. As a result, investors are beginning to look at the companies serving it through a broader investment lens. On September 18, Kirsten Chang, senior industry analyst at VettaFi, and Brendan Cavanaugh, chief investment officer at Defiance ETFs, will examine that opportunity during a free webinar titled: Investing in the Autism Care Economy: Inside the Defiance Autism Impact ETF.Key Takeaways CDC data shows that clinicians identified about 1 in 31 8-year-old children with autism. Autism care spans healthcare, technology, education, and behavioral services. The first-ever autism ETF, the Defiance Autism Impact ETF (ASD), launched in June 2026. Investing in the Autism Care EconomyAutism is increasingly recognized across communities in the U.S. The latest data from the Centers for Disease Control and Prevention (CDC) found that about 1 in 31 8-year-old children were identified with autism. That growing need supports demand across a wide range of services. The ecosystem includes healthcare providers, behavioral services, pharmaceuticals, diagnostics, specialized education, and assistive technologies. For investors, the question is whether those developments add up to a broader thematic opportunity. Advances in the industry are creating new areas of activity. At the same time, demand for autism-related services could shape the companies operating across these industries. Chang and Cavanaugh will discuss how those trends are reshaping the autism care landscape. Additionally, they will also examine what investors and advisors should consider when looking for exposure to companies operating across the theme. See More: How Autism Research ETF ASD Can Deliver for Your PortfolioHow the Defiance Autism Impact ETF (ASD) InvestsDefiance didn’t build the Defiance Autism Impact ETF (ASD) around a single autism drug or a bet on one company. Instead, the firm identified a broader network of businesses serving different parts of the autism ecosystem and built an ETF around it. ASD launched in June 2026 and tracks the VettaFi Autism Impact Index. The fund uses an equal-weight methodology and currently holds roughly 40 companies. The index invests across three broad areas: drugs and behavioral therapeutics, diagnostics and assessment, and specialized education and educational technology. The portfolio extends beyond pure-play autism companies. Holdings include Neuren Pharmaceuticals (NEU), LifeStance Health Group (LFST), and Acadia Healthcare Company (ACHC), among others. ASD charges a 0.79% expense ratio and has approximately $1.4 million in assets. Join the webcast on September 18 to learn more about how the autism care economy is evolving — and what it could mean for investors looking for opportunities beyond traditional market themes. For more news, information, and analysis, visit the Thematic Investing Content Hub. VettaFi LLC (“VettaFi”) is the index provider for ASD which it receives an index licensing fee. However, ASD is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of ASD.

More Commentary

From Models to Embodiment: Robotics Is the Next AI Investment Frontier
BY | ETF Database
6:59 am ET 09/01/26 | 20 VIEWS
Solana Surprise Could Lift This ETFs Fortunes
BY | ETF Database
10:45 am ET 09/01/26 | 9 VIEWS
Chinas AI Ambitions Come to Life in This ETF
BY | ETF Database
5:54 am ET 09/01/26 | 19 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.